These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 34453497)

  • 21. Glutathione S-transferase polymorphisms are not associated with population pharmacokinetic parameters of busulfan in pediatric patients.
    Zwaveling J; Press RR; Bredius RG; van Derstraaten TR; den Hartigh J; Bartelink IH; Boelens JJ; Guchelaar HJ
    Ther Drug Monit; 2008 Aug; 30(4):504-10. PubMed ID: 18641537
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intravenous busulfan in adults prior to haematopoietic stem cell transplantation: a population pharmacokinetic study.
    Nguyen L; Leger F; Lennon S; Puozzo C
    Cancer Chemother Pharmacol; 2006 Jan; 57(2):191-8. PubMed ID: 16133536
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The pharmacokinetics and pharmacodynamics of busulfan when combined with melphalan as conditioning in adult autologous stem cell transplant recipients.
    Willcox A; Wong E; Nath C; Janson B; Harrison SJ; Hoyt R; Bajel A; Shaw P; Ritchie D; Grigg A
    Ann Hematol; 2018 Dec; 97(12):2509-2518. PubMed ID: 30051172
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetic targeting of intravenous busulfan reduces conditioning regimen related toxicity following allogeneic hematopoietic cell transplantation for acute myelogenous leukemia.
    Pidala J; Kim J; Anasetti C; Kharfan-Dabaja MA; Nishihori T; Field T; Perkins J; Perez L; Fernandez HF
    J Hematol Oncol; 2010 Oct; 3():36. PubMed ID: 20925957
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Therapeutic drug monitoring of busulfan in transplantation.
    Russell JA; Kangarloo SB
    Curr Pharm Des; 2008; 14(20):1936-49. PubMed ID: 18691105
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes.
    Russell JA; Tran HT; Quinlan D; Chaudhry A; Duggan P; Brown C; Stewart D; Ruether JD; Morris D; Glick S; Gyonyor E; Andersson BS
    Biol Blood Marrow Transplant; 2002; 8(9):468-76. PubMed ID: 12374451
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Once-daily i.v. BU-based conditioning regimen before allogeneic hematopoietic SCT: a study of influence of GST gene polymorphisms on BU pharmacokinetics and clinical outcomes in Chinese patients.
    Yin J; Xiao Y; Zheng H; Zhang YC
    Bone Marrow Transplant; 2015 May; 50(5):696-705. PubMed ID: 25730183
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Body weight-dependent pharmacokinetics of busulfan in paediatric haematopoietic stem cell transplantation patients: towards individualized dosing.
    Bartelink IH; Boelens JJ; Bredius RG; Egberts AC; Wang C; Bierings MB; Shaw PJ; Nath CE; Hempel G; Zwaveling J; Danhof M; Knibbe CA
    Clin Pharmacokinet; 2012 May; 51(5):331-45. PubMed ID: 22455797
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Accurate targeting of daily intravenous busulfan with 8-hour blood sampling in hospitalized adult hematopoietic cell transplant recipients.
    Yeh RF; Pawlikowski MA; Blough DK; McDonald GB; O'Donnell PV; Rezvani A; Deeg HJ; McCune JS
    Biol Blood Marrow Transplant; 2012 Feb; 18(2):265-72. PubMed ID: 21736869
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The pharmacokinetics and safety of twice daily i.v. BU during conditioning in pediatric allo-SCT recipients.
    Le Gall JB; Milone MC; Waxman IM; Shaw LM; Harrison L; Duffy D; van de Ven C; Militano O; Geyer MB; Morris E; Bhatia M; Satwani P; George D; Garvin JH; Bradley MB; Schwartz J; Baxter-Lowe LA; Cairo MS
    Bone Marrow Transplant; 2013 Jan; 48(1):19-25. PubMed ID: 22684047
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Predictive performance of a busulfan pharmacokinetic model in children and young adults.
    Bartelink IH; van Kesteren C; Boelens JJ; Egberts TC; Bierings MB; Cuvelier GD; Wynn RF; Slatter MA; Chiesa R; Danhof M; Knibbe CA
    Ther Drug Monit; 2012 Oct; 34(5):574-83. PubMed ID: 22972539
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Glutathione S-transferase gene variations influence BU pharmacokinetics and outcome of hematopoietic SCT in pediatric patients.
    Ansari M; Rezgui MA; Théoret Y; Uppugunduri CR; Mezziani S; Vachon MF; Desjean C; Rousseau J; Labuda M; Przybyla C; Duval M; Champagne M; Peters C; Bittencourt H; Krajinovic M;
    Bone Marrow Transplant; 2013 Jul; 48(7):939-46. PubMed ID: 23292236
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of genetic polymorphisms in genes encoding GST isoenzymes on BU pharmacokinetics in adult patients undergoing hematopoietic SCT.
    ten Brink MH; Wessels JA; den Hartigh J; van der Straaten T; von dem Borne PA; Guchelaar HJ; Zwaveling J
    Bone Marrow Transplant; 2012 Feb; 47(2):190-5. PubMed ID: 21441958
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetic Modeling and Simulation with Pharmacogenetic Insights Support the Relevance of Therapeutic Drug Monitoring for Myeloablative Busulfan Dosing in Adult HSCT.
    Ben Hassine K; Seydoux C; Khier S; Daali Y; Medinger M; Halter J; Heim D; Chalandon Y; Schanz U; Nair G; Cantoni N; Passweg JR; Satyanarayana Uppugunduri CR; Ansari M
    Transplant Cell Ther; 2024 Mar; 30(3):332.e1-332.e15. PubMed ID: 38081414
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of Glutathione S-Transferase Polymorphisms on Busulfan Pharmacokinetics and Outcomes of Hematopoietic Stem Cell Transplantation.
    Al-Riyami I; Al-Khabori M; Al Balushi K; Al-Zadjali S; Al-Rawahi M; Dennison D; Al-Hunaini M; Al-Rawas A; Al-Moundhri M
    Ther Drug Monit; 2022 Aug; 44(4):527-534. PubMed ID: 34990437
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of combined test dose and therapeutic drug monitoring strategy in exposure-directed busulfan.
    Iemura T; Kondo T; Ueda A; Maeda T; Kitawaki T; Arai Y; Kanda J; Ikeda T; Imada K; Ishikawa T; Anzai N; Itoh M; Takeoka T; Akasaka T; Yago K; Yonezawa A; Arima N; Kitano T; Nohgawa M; Watanabe M; Moriguchi T; Yamashita K; Ueda Y; Matsumoto K; Takaori-Kondo A
    Ann Hematol; 2023 Oct; 102(10):2909-2922. PubMed ID: 37052663
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Therapeutic Drug Monitoring of Busulfan for the Management of Pediatric Patients: Cross-Validation of Methods and Long-Term Performance.
    Choong E; Uppugunduri CRS; Marino D; Kuntzinger M; Doffey-Lazeyras F; Lo Piccolo R; Chalandon Y; Peters C; Daali Y; Ansari M
    Ther Drug Monit; 2018 Feb; 40(1):84-92. PubMed ID: 29189665
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reliability of a pretransplant i.v. BU test dose performed 2 weeks before myeloablative FluBu conditioning regimen.
    Beri R; Chunduri S; Sweiss K; Peace DJ; Mactal-Haaf C; Dobogai LC; Shord S; Quigley JG; Chen YH; Mahmud N; Rondelli D
    Bone Marrow Transplant; 2010 Feb; 45(2):249-53. PubMed ID: 19543331
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Single Daily Busulfan Dosing for Infants with Nonmalignant Diseases Undergoing Reduced-Intensity Conditioning for Allogeneic Hematopoietic Progenitor Cell Transplantation.
    Ward J; Kletzel M; Duerst R; Fuleihan R; Chaudhury S; Schneiderman J; Tse WT
    Biol Blood Marrow Transplant; 2015 Sep; 21(9):1612-21. PubMed ID: 26025482
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of genetic variants GSTA1 and CYP39A1 and age on busulfan clearance in pediatric patients undergoing hematopoietic stem cell transplantation.
    ten Brink MH; van Bavel T; Swen JJ; van der Straaten T; Bredius RG; Lankester AC; Zwaveling J; Guchelaar HJ
    Pharmacogenomics; 2013 Nov; 14(14):1683-90. PubMed ID: 24192117
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.